| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |





From the Cardiology Research Laboratory,* Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania; the Departments of Medicine and Pharmacology,
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania; and Wyeth-Ayerst Research,
Princeton, New Jersey
Serotonin [5-hydroxytryptamine (5-HT)]-mediated cardiac valvular disease has been commonly observed in patients with carcinoid tumors. Previous research by others using reverse transcriptase-polymerase chain reaction demonstrated that aortic valve cells expressed predominantly 5-HT2A/2B receptors (5-HT2AR). Related investigations by our group using sheep aortic valve interstitial cell (SAVIC) cultures demonstrated that 5-HT both up-regulates transforming growth factor (TGF)-ß1 expression and activity, and also results in increased phospholipase C (PLC) activity. Thus, the present study investigated the hypothesis that the 5-HT signaling pathway in SAVICs involves 5-HT2Rs with associated G-protein signal transduction. The objectives were to functionally characterize in SAVIC cultures the native serotonin receptor subtypes using specific agonists and antagonists, and to delineate the serotonin-signaling pathway. 5-HT administration caused a marked stimulation of PLC activity. SAVIC studies of specific agents that target the 5-HT2R subtypes indicate that this response seemed to be mediated predominantly by 5-HT2ARs. Furthermore, the sheep 5-HT2AR was identified by reverse transcriptase-polymerase chain reaction with sequence confirmation including comparisons to pig and human 5-HT2AR. Extracellular signal-regulated kinase (Erk 1/2) is a signaling molecule downstream from the 5-HT2AR. Both a protein kinase C inhibitor, GF109203X, and a Src inhibitor, PP1, attenuated 5-HT-stimulated Erk 1/2 activation. However, a 5-HT2AR antagonist, MDL 100907, inhibited 5-HT up-regulation of PLC and TGF-ß1, while having far less pronounced effects on Erk 1/2. In conclusion, these studies of the signal transduction activity of SAVICs in response to 5-HT have demonstrated that the 5-HT2ARs are the most functionally active of the 5-HT2Rs in this cell type. Furthermore, 5-HT2ARs are also involved in 5-HT up-regulation of active TGF-ß. 5-HT also mediated strong Erk 1/2 signaling via the MAP-kinase pathway, which was only in part because of 5-HT2AR activity. Thus, major 5-HT Erk 1/2 signaling beyond that controlled by 5-HT2Rs must involve other serotonin receptor types and/or secondary signaling events.
This article has been cited by other articles:
![]() |
X. Gu and K. S. Masters Role of the MAPK/ERK pathway in valvular interstitial cell calcification Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1748 - H1757. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Liu and A. I. Gotlieb Transforming Growth Factor-{beta} Regulates in Vitro Heart Valve Repair by Activated Valve Interstitial Cells Am. J. Pathol., November 1, 2008; 173(5): 1275 - 1285. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fabre, J. Marchal-Somme, S. Marchand-Adam, C. Quesnel, R. Borie, M. Dehoux, C. Ruffie, J. Callebert, J-M. Launay, D. Henin, et al. Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice Eur. Respir. J., August 1, 2008; 32(2): 426 - 436. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Gornemann, H. Hubner, P. Gmeiner, R. Horowski, K. P. Latte, M. Flieger, and H. H. Pertz Characterization of the Molecular Fragment That Is Responsible for Agonism of Pergolide at Serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A Receptors J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1136 - 1145. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Donnelly Cardiac Valvular Pathology: Comparative Pathology and Animal Models of Acquired Cardiac Valvular Diseases Toxicol Pathol, February 1, 2008; 36(2): 204 - 217. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Liu, V. R. Joag, and A. I. Gotlieb The Emerging Role of Valve Interstitial Cell Phenotypes in Regulating Heart Valve Pathobiology Am. J. Pathol., November 1, 2007; 171(5): 1407 - 1418. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Droogmans, P. R. Franken, C. Garbar, C. Weytjens, B. Cosyns, T. Lahoutte, V. Caveliers, M. Pipeleers-Marichal, A. Bossuyt, D. Schoors, et al. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology Eur. Heart J., September 1, 2007; 28(17): 2156 - 2162. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ogden, J. M. Thompson, Z. Hickner, T. Huang, D. D. Tang, and S. W. Watts A new signaling paradigm for serotonin: use of Crk-associated substrate in arterial contraction Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2857 - H2863. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-J. Liang, L.-P. Lai, B.-W. Wang, S.-J. Juang, C.-M. Chang, J.-G. Leu, and K.-G. Shyu Mechanical stress enhances serotonin 2B receptor modulating brain natriuretic peptide through nuclear factor-{kappa}B in cardiomyocytes Cardiovasc Res, November 1, 2006; 72(2): 303 - 312. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Levy Serotonin Transporter Mechanisms and Cardiac Disease Circulation, January 3, 2006; 113(1): 2 - 4. [Full Text] [PDF] |
||||
![]() |
A. Mekontso-Dessap, F. Brouri, O. Pascal, P. Lechat, N. Hanoun, L. Lanfumey, I. Seif, N. Benhaiem-Sigaux, M. Kirsch, M. Hamon, et al. Deficiency of the 5-Hydroxytryptamine Transporter Gene Leads to Cardiac Fibrosis and Valvulopathy in Mice Circulation, January 3, 2006; 113(1): 81 - 89. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Miller SEROTONIN 5-HT2C RECEPTOR AGONISTS: POTENTIAL FOR THE TREATMENT OF OBESITY Mol. Interv., October 1, 2005; 5(5): 282 - 291. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Elangbam, R. M. Lightfoot, L. W. Yoon, D. R. Creech, R. S. Geske, C. W. Crumbley, L. D. Gates, and H. G. Wall 5-Hydroxytryptamine (5HT) Receptors in the Heart Valves of Cynomolgus Monkeys and Sprague-Dawley Rats J. Histochem. Cytochem., May 1, 2005; 53(5): 671 - 677. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. I. Gustafsson, K. Tommeras, I. Nordrum, J. P. Loennechen, A. Brunsvik, E. Solligard, R. Fossmark, I. Bakke, U. Syversen, and H. Waldum Long-Term Serotonin Administration Induces Heart Valve Disease in Rats Circulation, March 29, 2005; 111(12): 1517 - 1522. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G. Nebigil and L. Maroteaux Functional Consequence of Serotonin/5-HT2B Receptor Signaling in Heart: Role of Mitochondria in Transition Between Hypertrophy and Heart Failure? Circulation, August 19, 2003; 108(7): 902 - 908. [Full Text] [PDF] |
||||
![]() |
V. Setola, S. J. Hufeisen, K. J. Grande-Allen, I. Vesely, R. A. Glennon, B. Blough, R. B. Rothman, and B. L. Roth 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") Induces Fenfluramine-Like Proliferative Actions on Human Cardiac Valvular Interstitial Cells in Vitro Mol. Pharmacol., June 1, 2003; 63(6): 1223 - 1229. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Jian, J. Xu, J. Connolly, R. C. Savani, N. Narula, B. Liang, and R. J. Levy Serotonin Mechanisms in Heart Valve Disease I: Serotonin-Induced Up-Regulation of Transforming Growth Factor-{beta}1 via G-Protein Signal Transduction in Aortic Valve Interstitial Cells Am. J. Pathol., December 1, 2002; 161(6): 2111 - 2121. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |